LymphedemaV1, Ncbi, Checkpoint, bibRecord, 003789

A Novel Intralymphatic Nanocarrier-Delivery System for Cisplatin Therapy in Breast Cancer with Improved Tumor Efficacy and Lower Systemic Toxicity In Vivo

Identifieur interne : 003789 ( Ncbi/Checkpoint ); précédent : 003788; suivant : 003790

A Novel Intralymphatic Nanocarrier-Delivery System for Cisplatin Therapy in Breast Cancer with Improved Tumor Efficacy and Lower Systemic Toxicity In Vivo

Auteurs : Mark S. Cohen [États-Unis] ; Shuang Cai [États-Unis] ; Yumei Xie [États-Unis] ; M. Laird Forrest [États-Unis]

Source :

American journal of surgery [ 0002-9610 ] ; 2009.

RBID : PMC:2791715

Abstract

Background

A lymphatically delivered nanoconjugate of cisplatin was evaluated in an orthotopic mouse model of locoregionally metastatic breast cancer (LABC) to determine if it can overcome some of the limitations of standard cisplatin therapy such as high systemic toxicity.

Methods

Human breast cancer cells (10⁷ MDA-MB-468LN) were injected into the mammary fat pad of female nu/nu mice. Once tumor volume reached 50 mm³; intravenous cisplatin or subcutaneous hyaluronan-cisplatin [HA-cisplatin] nanoconjugate was given 1/week × 3 at 3.3 mg/kg (platinum basis).

Results

Nanoconjugates co-localized with the tumors after subcutaneous peritumoral injection and demonstrated improved efficacy to intravenous cisplatin. After one month, renal tubular hemorrhage and edema were more prevalent in the intravenous formulation compared to subcutaneous HA-cisplatin nanoconjugates.

Conclusions

This nanocarrier delivery platform focuses drug in the areas where tumor burden is greatest, potentially reducing systemic toxicity, and has future applicability as a neoadjuvant or adjuvant therapy for LABC.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791715

DOI: 10.1016/j.amjsurg.2009.07.032
PubMed: 19969129
PubMed Central: 2791715

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: 002758
to stream Pmc, to step Curation: 002757
to stream Pmc, to step Checkpoint: 003836
to stream Ncbi, to step Merge: 003789
to stream Ncbi, to step Curation: 003789

Links to Exploration step

PMC:2791715

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A Novel Intralymphatic Nanocarrier-Delivery System for Cisplatin Therapy in Breast Cancer with Improved Tumor Efficacy and Lower Systemic Toxicity In Vivo</title>
<author><name sortKey="Cohen, Mark S" sort="Cohen, Mark S" uniqKey="Cohen M" first="Mark S." last="Cohen">Mark S. Cohen</name>
<affiliation wicri:level="2"><nlm:aff id="A1"> Department of Surgery, University of Kansas Medical Center, Rm. 2035 Sutherland Institute MS-1037, 3901 Rainbow Blvd., Kansas City, Kansas 66160</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
<wicri:cityArea> Department of Surgery, University of Kansas Medical Center, Rm. 2035 Sutherland Institute MS-1037, 3901 Rainbow Blvd., Kansas City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cai, Shuang" sort="Cai, Shuang" uniqKey="Cai S" first="Shuang" last="Cai">Shuang Cai</name>
<affiliation wicri:level="2"><nlm:aff id="A2"> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence, Kansas 66047</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
<wicri:cityArea> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Xie, Yumei" sort="Xie, Yumei" uniqKey="Xie Y" first="Yumei" last="Xie">Yumei Xie</name>
<affiliation wicri:level="2"><nlm:aff id="A2"> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence, Kansas 66047</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
<wicri:cityArea> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Forrest, M Laird" sort="Forrest, M Laird" uniqKey="Forrest M" first="M. Laird" last="Forrest">M. Laird Forrest</name>
<affiliation wicri:level="2"><nlm:aff id="A2"> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence, Kansas 66047</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
<wicri:cityArea> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">19969129</idno>
<idno type="pmc">2791715</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791715</idno>
<idno type="RBID">PMC:2791715</idno>
<idno type="doi">10.1016/j.amjsurg.2009.07.032</idno>
<date when="2009">2009</date>
<idno type="wicri:Area/Pmc/Corpus">002758</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002758</idno>
<idno type="wicri:Area/Pmc/Curation">002757</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002757</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003836</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003836</idno>
<idno type="wicri:Area/Ncbi/Merge">003789</idno>
<idno type="wicri:Area/Ncbi/Curation">003789</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003789</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">A Novel Intralymphatic Nanocarrier-Delivery System for Cisplatin Therapy in Breast Cancer with Improved Tumor Efficacy and Lower Systemic Toxicity In Vivo</title>
<author><name sortKey="Cohen, Mark S" sort="Cohen, Mark S" uniqKey="Cohen M" first="Mark S." last="Cohen">Mark S. Cohen</name>
<affiliation wicri:level="2"><nlm:aff id="A1"> Department of Surgery, University of Kansas Medical Center, Rm. 2035 Sutherland Institute MS-1037, 3901 Rainbow Blvd., Kansas City, Kansas 66160</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
<wicri:cityArea> Department of Surgery, University of Kansas Medical Center, Rm. 2035 Sutherland Institute MS-1037, 3901 Rainbow Blvd., Kansas City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cai, Shuang" sort="Cai, Shuang" uniqKey="Cai S" first="Shuang" last="Cai">Shuang Cai</name>
<affiliation wicri:level="2"><nlm:aff id="A2"> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence, Kansas 66047</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
<wicri:cityArea> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Xie, Yumei" sort="Xie, Yumei" uniqKey="Xie Y" first="Yumei" last="Xie">Yumei Xie</name>
<affiliation wicri:level="2"><nlm:aff id="A2"> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence, Kansas 66047</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
<wicri:cityArea> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Forrest, M Laird" sort="Forrest, M Laird" uniqKey="Forrest M" first="M. Laird" last="Forrest">M. Laird Forrest</name>
<affiliation wicri:level="2"><nlm:aff id="A2"> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence, Kansas 66047</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Kansas</region>
</placeName>
<wicri:cityArea> Department of Pharmaceutical Chemistry, 2095 Constant Ave, University of Kansas, Lawrence</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">American journal of surgery</title>
<idno type="ISSN">0002-9610</idno>
<idno type="eISSN">1879-1883</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec id="S1"><title>Background</title>
<p id="P2">A lymphatically delivered nanoconjugate of cisplatin was evaluated in an orthotopic mouse model of locoregionally metastatic breast cancer (LABC) to determine if it can overcome some of the limitations of standard cisplatin therapy such as high systemic toxicity.</p>
</sec>
<sec sec-type="methods" id="S2"><title>Methods</title>
<p id="P3">Human breast cancer cells (10<sup>7</sup>
 MDA-MB-468LN) were injected into the mammary fat pad of female nu/nu mice. Once tumor volume reached 50 mm<sup>3</sup>
; intravenous cisplatin or subcutaneous hyaluronan-cisplatin [HA-cisplatin] nanoconjugate was given 1/week × 3 at 3.3 mg/kg (platinum basis).</p>
</sec>
<sec id="S3"><title>Results</title>
<p id="P4">Nanoconjugates co-localized with the tumors after subcutaneous peritumoral injection and demonstrated improved efficacy to intravenous cisplatin. After one month, renal tubular hemorrhage and edema were more prevalent in the intravenous formulation compared to subcutaneous HA-cisplatin nanoconjugates.</p>
</sec>
<sec id="S4"><title>Conclusions</title>
<p id="P5">This nanocarrier delivery platform focuses drug in the areas where tumor burden is greatest, potentially reducing systemic toxicity, and has future applicability as a neoadjuvant or adjuvant therapy for LABC.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Kansas</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Kansas"><name sortKey="Cohen, Mark S" sort="Cohen, Mark S" uniqKey="Cohen M" first="Mark S." last="Cohen">Mark S. Cohen</name>
</region>
<name sortKey="Cai, Shuang" sort="Cai, Shuang" uniqKey="Cai S" first="Shuang" last="Cai">Shuang Cai</name>
<name sortKey="Forrest, M Laird" sort="Forrest, M Laird" uniqKey="Forrest M" first="M. Laird" last="Forrest">M. Laird Forrest</name>
<name sortKey="Xie, Yumei" sort="Xie, Yumei" uniqKey="Xie Y" first="Yumei" last="Xie">Yumei Xie</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003789 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 003789 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    RBID
   |clé=     PMC:2791715
   |texte=   A Novel Intralymphatic Nanocarrier-Delivery System for Cisplatin Therapy in Breast Cancer with Improved Tumor Efficacy and Lower Systemic Toxicity In Vivo
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i   -Sk "pubmed:19969129" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

A Novel Intralymphatic Nanocarrier-Delivery System for Cisplatin Therapy in Breast Cancer with Improved Tumor Efficacy and Lower Systemic Toxicity In Vivo

A Novel Intralymphatic Nanocarrier-Delivery System for Cisplatin Therapy in Breast Cancer with Improved Tumor Efficacy and Lower Systemic Toxicity In Vivo

Source :

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki